San Diego, California-based Viriom Inc. signed a licensing agreement with PT Lloyd Pharma Indonesia for Elpida as well as other drugs from Viriom’s HIV (human immunodeficiency virus) and HBV (hepatitis B virus) portfolio. Viriom’s agreement with PT Lloyd will enable technology transfer, primary and secondary packaging and drug Manufacturing in Indonesia. Elpida, its flagship drug is currently offered as daily 20 mg capsules to treat HIV-1 infections, and is currently being developed worldwide as a once-a-week oral therapy in combination with other Antiretroviral (ARV) therapies.
Indonesia aims to reach the goals under the UNAIDS 90-90-90 strategy, which sees 90% of HIV infected people diagnosed, 90% of the diagnosed to be prescribed an ARV and 90% to reach an undetectable viral load. Around 21% of patients in Indonesia are currently receiving ARVs under the government Medical program. The government plans to treat at least 40% of its 640,000 HIV-positive patients by 2020. 95% of ARVs offered to patients in Indonesia are generic. Pregnant women and the prevention of mother-to-child transmission will be given special attention in government programs.
(Source: Viriom Inc, PR Newswire)